Pascale Cony-Makhoul

5PUBLICATIONS
13CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCardiovascular medicine and haematology not elsewhere classifiedLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 22, 2021
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

Jim Canet, Pascale Cony-Makhoul, Sébastien Orazio

|Jul 01, 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.

Philippe Rousselot, Luigina Mollica, Joëlle Guilhot

|Jun 21, 2021
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.

Thibault Comont, Mathieu Meunier, Amina Cherait

|Jul 05, 2019
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.

Marc G Berger, Bruno Pereira, Philippe Rousselot

|Dec 22, 2017
Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.

Pascale Cony-Makhoul, Martine Gardembas, Valérie Coiteux

Pageof 1

Frequent Collaborators

2 joint publications

Delphine Réa

2 joint publications

Gabriel Etienne

1 joint publications

Marc G Berger

1 joint publications

Kamel Laribi